Press-release for stocks related to dupixent for sny

tags : Dupixent symbols : Sny

save search

Incyte Gets Phase II Win, Targets Blockbuster Dupixent in Skin Disease
Published: 2024-03-11 (Crawled : 16:00) - biospace.com/
SNY | News | $45.395 -1.55% -1.58% 4.4M

Health Technology

| -4.06% | O: 0.57% H: 0.0% C: 0.0%
disease dupixent skin

Sanofi, Regeneron Secure FDA Priority Review for Dupixent in COPD
Published: 2024-02-23 (Crawled : 15:00) - biospace.com/
SNY | News | $45.395 -1.55% -1.58% 4.4M

Health Technology

| -3.77% | O: 0.97% H: 0.0% C: 0.0%
fda dupixent review copd

Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of COPD with Type 2 Inflammation
Published: 2024-02-23 (Crawled : 06:00) - globenewswire.com
SNY | News | $45.395 -1.55% -1.58% 4.4M

Health Technology

| -3.77% | O: 0.97% H: 0.0% C: 0.0%
REGN | $893.66 -0.84% -0.84% 450K

Health Technology

| -6.6% | O: 1.05% H: 1.09% C: 0.64%
dupixent fda review treatment copd

Press Release: Dupixent® sBLA accepted for FDA Priority Review for treatment of COPD with type 2 inflammation
Published: 2024-02-23 (Crawled : 06:00) - globenewswire.com
SNY | News | $45.395 -1.55% -1.58% 4.4M

Health Technology

| -3.77% | O: 0.97% H: 0.0% C: 0.0%
REGN | $893.66 -0.84% -0.84% 450K

Health Technology

| -6.6% | O: 1.05% H: 1.09% C: 0.64%
dupixent fda review treatment copd

Press Release: Japan first in the world to approve Dupixent® for chronic spontaneous urticaria (CSU)
Published: 2024-02-16 (Crawled : 06:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 1.4K

Health Technology

| 0.42% | O: 1.66% H: 0.0% C: -1.59%
SNY | News | $45.395 -1.55% -1.58% 4.4M

Health Technology

| -0.86% | O: -0.6% H: 0.0% C: 0.0%
REGN | $893.66 -0.84% -0.84% 450K

Health Technology

| -5.61% | O: -0.14% H: 0.32% C: -0.57%
dupixent first japan urticaria world

Japan First in the World to Approve Dupixent® (dupilumab) for Chronic Spontaneous Urticaria (CSU)
Published: 2024-02-16 (Crawled : 06:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 1.4K

Health Technology

| 0.42% | O: 1.66% H: 0.0% C: -1.59%
SNY | News | $45.395 -1.55% -1.58% 4.4M

Health Technology

| -0.86% | O: -0.6% H: 0.0% C: 0.0%
REGN | $893.66 -0.84% -0.84% 450K

Health Technology

| -5.61% | O: -0.14% H: 0.32% C: -0.57%
dupixent first japan urticaria world

FDA Decisions: Sanofi/Regeneron's Dupixent Racks Up Another Pediatric Indication
Published: 2024-02-02 (Crawled : 15:00) - biospace.com/
PRGO | $29.94 -0.33% 0.0% 970K

Health Technology

| -6.94% | O: -0.53% H: 1.28% C: 0.53%
JNJ | News | $145.74 0.67% 0.0% 9.3M

Health Technology

| -8.41% | O: -0.15% H: 0.0% C: 0.0%
ABT | News | $105.27 -0.6% -0.15% 7.3M

Health Technology

| -5.73% | O: -0.57% H: 0.0% C: 0.0%
SNY | News | $45.395 -1.55% -1.58% 4.4M

Health Technology

| -4.85% | O: -0.93% H: 0.0% C: 0.0%
fda dupixent

Sanofi, Regeneron Win Dupixent Label Expansion to Treat Eosinophilic Esophagitis
Published: 2024-01-26 (Crawled : 15:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 1.4K

Health Technology

| -6.6% | O: 1.8% H: 0.0% C: -1.82%
SNY | News | $45.395 -1.55% -1.58% 4.4M

Health Technology

| -7.6% | O: 0.5% H: 0.0% C: 0.0%
label dupixent treat expansion

FDA Decisions: Sanofi/Regeneron's Dupixent Racks Up Another Pediatric Indication
Published: 2024-01-26 (Crawled : 14:30) - biospace.com/
SNYNF | News | $92.7 -2.18% 1.4K

Health Technology

| -6.6% | O: 1.8% H: 0.0% C: -1.82%
PRGO | $29.94 -0.33% 0.0% 970K

Health Technology

| -9.3% | O: 0.72% H: 0.45% C: 0.24%
JNJ | News | $145.74 0.67% 0.0% 9.3M

Health Technology

| -9.0% | O: 0.8% H: 0.0% C: 0.0%
ABT | News | $105.27 -0.6% -0.15% 7.3M

Health Technology

| -4.02% | O: 0.68% H: 0.0% C: 0.0%
SNY | News | $45.395 -1.55% -1.58% 4.4M

Health Technology

| -7.6% | O: 0.5% H: 0.0% C: 0.0%
fda dupixent

Dupixent® (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE)
Published: 2024-01-25 (Crawled : 20:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 1.4K

Health Technology

| -6.6% | O: 1.8% H: 0.0% C: -1.82%
SNY | News | $45.395 -1.55% -1.58% 4.4M

Health Technology

| -7.6% | O: 0.5% H: 0.0% C: 0.0%
REGN | $893.66 -0.84% -0.84% 450K

Health Technology

| -5.02% | O: 0.33% H: 0.65% C: -1.26%
dupixent fda first children approved year treatment

Press Release: Dupixent® FDA approved as first and only treatment indicated for children aged 1 year and older with eosinophilic esophagitis (EoE)
Published: 2024-01-25 (Crawled : 20:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 1.4K

Health Technology

| -6.6% | O: 1.8% H: 0.0% C: -1.82%
SNY | News | $45.395 -1.55% -1.58% 4.4M

Health Technology

| -7.6% | O: 0.5% H: 0.0% C: 0.0%
REGN | $893.66 -0.84% -0.84% 450K

Health Technology

| -5.02% | O: 0.33% H: 0.65% C: -1.26%
dupixent fda first children approved year treatment

Dupixent® (dupilumab) U.S. Label Updated with Data Further Supporting Use in Atopic Dermatitis with Moderate-to-Severe Hand and Foot Involvement
Published: 2024-01-16 (Crawled : 12:00) - globenewswire.com
SNYNF | News | $92.7 -2.18% 1.4K

Health Technology

| -12.55% | O: -2.03% H: 0.05% C: 0.05%
SNY | News | $45.395 -1.55% -1.58% 4.4M

Health Technology

| -11.95% | O: -1.34% H: 0.0% C: 0.0%
REGN | $893.66 -0.84% -0.84% 450K

Health Technology

| -3.43% | O: -0.21% H: 0.67% C: 0.66%
dupixent label dermatitis

Deals, Dupixent and GLP-1 drug shortages
Published: 2023-11-29 (Crawled : 15:30) - biospace.com/
SNY | News | $45.395 -1.55% -1.58% 4.4M

Health Technology

| -1.85% | O: -0.15% H: 0.07% C: -0.66%
drug dupixent

Regeneron and Sanofi Find Further Positive Results for Dupixent in COPD
Published: 2023-11-27 (Crawled : 17:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 1.4K

Health Technology